Trump Expected to Impose New Tariffs on Certain Pharmaceutical Drugs/ TezzBuzz/ WASHINGTON/ J. Mansour/ Morning Edition/ President Trump is expected to impose tariffs on pharmaceutical imports tied to drug pricing negotiations. Companies that refuse direct-to-consumer pricing deals could face tariffs up to 100%. The move is part of Trump’s broader trade and drug pricing strategy.
- Trump plans tariffs on pharmaceutical imports
- 100% tariff possible on patented drugs
- Tariffs tied to “Most Favored Nation” pricing plan
- Companies can avoid tariffs through negotiations
- Incentives offered to move production to U.S.
- Tariff rate could drop to 20% temporarily
- Policy may roll out as soon as Thursday
- Supreme Court ruling prompted new tariff strategy
- GOP concerns about rising drug prices
- Deals already reached with several drugmakers
- Limited number of drugs covered so far
- Tariffs could expand negotiations with industry
WASHINGTON — President Donald Trump is expected to impose new tariffs on certain pharmaceutical imports, targeting drugmakers that have not agreed to sell medications directly to consumers under his administration’s “Most Favored Nation” pricing initiative.
According to a draft order obtained by CNN, the proposed tariffs would apply to patented medications and their active pharmaceutical ingredients imported into the United States. Companies that do not participate in the administration’s pricing initiative could face tariffs as high as 100%.
The draft order is not yet final and could still change before being formally announced. However, sources familiar with the matter say Trump is expected to unveil the tariffs as soon as Thursday afternoon.
Incentives to Negotiate or Move Production
The proposed tariffs are designed to pressure pharmaceutical companies into negotiating lower drug prices or shifting manufacturing to the United States.
Under the draft plan, companies that strike agreements with the administration could avoid the full tariff. Drugmakers that commit to moving production to the U.S. could see tariffs reduced to 20% for four years. However, those reduced rates would revert to 100% beginning in 2030.
The administration has already negotiated deals with more than a dozen pharmaceutical companies to sell certain drugs directly to consumers. These agreements are part of Trump’s “Most Favored Nation” initiative, which aims to align U.S. drug prices with lower prices paid in other countries.
However, the initiative currently applies to a limited number of medications, many of which already have generic alternatives available at lower costs.
Trade Strategy After Supreme Court Ruling
The proposed pharmaceutical tariffs also mark a broader effort by Trump to revive his aggressive trade policies. In February, the Supreme Court ruled that some of the administration’s earlier tariffs were unconstitutional, limiting Trump’s ability to impose sweeping import taxes.
Trump sharply criticized the ruling and vowed to pursue alternative regulatory pathways to implement tariffs.
The new pharmaceutical tariffs would represent one of the first major moves in that renewed trade strategy.
Concerns About Drug Prices
Some Republican lawmakers and industry analysts have raised concerns that tariffs could increase drug prices rather than reduce them. Tariffs often raise costs for importers, which may be passed on to consumers.
Supporters of the policy argue that increased domestic production and negotiated pricing agreements could eventually lower costs.
The White House has not yet provided official comment on the draft order. Bloomberg first reported details of the proposed tariffs.
Broader Policy Goals
Trump’s administration has framed the tariff strategy as part of a broader push to:
- Lower prescription drug prices
- Increase domestic pharmaceutical manufacturing
- Reduce reliance on foreign drug supply chains
- Expand direct-to-consumer pricing agreements
The proposed tariffs could push more companies to negotiate with the administration or relocate manufacturing operations to the United States.
With the policy expected to be announced soon, the pharmaceutical industry and investors are closely watching how the administration finalizes the details and whether exemptions will be included.
As Trump continues to reshape trade and healthcare policy, the proposed drug tariffs could have significant implications for drug pricing, pharmaceutical manufacturing, and global trade relations.
More on US News
Comments are closed.